|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"melzer cohen c"
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2023-10-03 |
Estimated glomerular filtration rate, albuminuria, and adverse outcomes: An individual-participant data meta-analysis
|
Grams, ME; Coresh, J; Matsushita, K; Ballew, SH; Sang, Y; Surapaneni, A; Alencar de Pinho, N; Anderson, A; Appel, LJ; Ärnlöv, J; Azizi, F; Bansal, N; Bell, S; Bilo, HJG; Brunskill, NJ; Carrero, JJ; Chadban, S; Chalmers, J; Chen, J; Ciemins, E; Cirillo, M; Ebert, N; Evans, M; Ferreiro, A; Fu, EL; Fukagawa, M; Green, JA; Gutierrez, OM; Herrington, WG; Hwang, SJ; Inker, LA; Iseki, K; Jafar, T; Jassal, SK; Jha, V; Kadota, A; Katz, R; Köttgen, A; Konta, T; Kronenberg, F; Lee, BJ; Lees, J; Levin, A; Looker, HC; Major, R; Melzer Cohen, C; Mieno, M; Miyazaki, M; Moranne, O; Muraki, I; Naimark, D; Nitsch, D; Oh, W; Pena, M; Purnell, TS; Sabanayagam, C; Satoh, M; Sawhney, S; Schaeffner, E; Schöttker, B; Shen, JI; Shlipak, MG; Sinha, S; Stengel, B; Sumida, K; Tonelli, M; Valdivielso, JM; van Zuilen, AD; Visseren, FLJ; Wang, AYM; Wen, CP; Wheeler, DC; Yatsuya, H; Yamagata, K; Yang, JW; Young, A; Zhang, H; Zhang, L; Levey, AS; Gansevoort, RT |
| 國家衛生研究院 |
2023-08-31 |
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
|
Vistisen, D; Carstensen, B; Elisabetta, P; Lanzinger, S; Tan, ECH; Yabe, D; Kim, DJ; Sheu, WHH; Melzer-Cohen, C; Holl, RW; Núñez, J; Ha, KH; Halvorsen, S; Langslet, G; Karasik, A; Nyström, T; Niskanen, L; Guleria, S; Klement, R; Carrasco, M; Foersch, J; Shay, C; Koeneman, L; Hoti, F; Farsani, SF; Khunti, K; Zaccardi, F; Subramanian, A; Nirantharakumar, K; EMPRISE EU and East Asia Study Group |
| 臺大學術典藏 |
2020-06-01T09:06:46Z |
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
|
Heerspink H.J.L.;Karasik A.;Thuresson M.;Melzer-Cohen C.;Chodick G.;Khunti K.;Wilding J.P.H.;Garcia Rodriguez L.A.;Cea-Soriano L.;Kohsaka S.;Nicolucci A.;Lucisano G.;Lin F.-J.;Chih-Yuan Wang;Wittbrodt E.;Fenici P.;Kosiborod M.; Heerspink H.J.L.; Karasik A.; Thuresson M.; Melzer-Cohen C.; Chodick G.; Khunti K.; Wilding J.P.H.; Garcia Rodriguez L.A.; Cea-Soriano L.; Kohsaka S.; Nicolucci A.; Lucisano G.; Lin F.-J.; CHIH-YUAN WANG; Wittbrodt E.; Fenici P.; Kosiborod M. |
| 臺大學術典藏 |
2020-06-01T09:06:46Z |
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
|
Heerspink H.J.L.;Karasik A.;Thuresson M.;Melzer-Cohen C.;Chodick G.;Khunti K.;Wilding J.P.H.;Garcia Rodriguez L.A.;Cea-Soriano L.;Kohsaka S.;Nicolucci A.;Lucisano G.;Lin F.-J.;Chih-Yuan Wang;Wittbrodt E.;Fenici P.;Kosiborod M.; Heerspink H.J.L.; Karasik A.; Thuresson M.; Melzer-Cohen C.; Chodick G.; Khunti K.; Wilding J.P.H.; Garcia Rodriguez L.A.; Cea-Soriano L.; Kohsaka S.; Nicolucci A.; Lucisano G.; Lin F.-J.; CHIH-YUAN WANG; Wittbrodt E.; Fenici P.; Kosiborod M. |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
